Starget Pharma
Developing Smart Targeted Radioligands (STRs) for precision oncology in hard-to-treat solid tumors.
Website: https://stargetpharma.com/
PUBLIC
| Field | Value |
|---|---|
| Name | Starget Pharma |
| Tagline | Developing Smart Targeted Radioligands (STRs) for precision oncology in hard-to-treat solid tumors. |
| Headquarters | Ramat Hasharon, Israel |
| Founded | 2019 |
| Stage | Series A |
| Business Model | Other (Biotech / Clinical-stage) |
| Industry | Healthtech |
| Technology | Biotech / Life Sciences |
| Geography | Middle East / North Africa |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding Label | $10M+ (total disclosed ~$38M) |
Links
PUBLIC
- Website: https://stargetpharma.com/
- LinkedIn: https://www.linkedin.com/company/starget-pharma-ltd
Executive Summary
PUBLIC Starget Pharma is a clinical-stage radiopharmaceutical startup developing a novel class of peptide-based radioligands for cancers with limited treatment options, a bet that merits attention due to its combination of proprietary chemistry, AI-augmented design, and a strategic U.S. manufacturing partnership timed for clinical entry [Calcalist/CTech, 2026]. Founded in 2019 in Israel, the company has built its platform around a proprietary "Backbone Dynamics" peptide chemistry designed to generate highly specific targeting agents for both imaging and therapy, a dual-use approach known as theranostics [Starget, Unknown]. The founding team, led by CEO Sigal Kalmanson Cusnir and co-founder Ronen Clemson, brings experience from the Israeli biotech ecosystem, with Clemson having a track record as a co-founder of Urogen Pharma Ltd., though detailed public biographies for the core scientific leadership are limited [Equilar ExecAtlas, Unknown]. To date, Starget has raised a total of $38 million, including an $18 million Series A round in February 2026 led by Ilex Medical alongside U.S. investors, capital earmarked for advancing its pipeline toward clinical development [PR Newswire, Feb 2026]. The company's immediate wedge is a collaboration with the Center for Molecular Imaging and Therapy (CMIT) in Louisiana, which provides an end-to-end pathway for clinical trial support and production, a critical scaling asset for a non-U.S. biotech [Morningstar, Feb 2026]. Over the next 12-18 months, investors should watch for the initiation of multiple clinical trials announced for 2026, which will serve as the first public validation points for its platform's efficacy and its ability to execute on the U.S. expansion strategy [Investing.com, Feb 2026].
Data Accuracy: GREEN -- Core claims (founding, funding total, Series A details, technology description) are confirmed by multiple independent sources including Calcalist/CTech, PR Newswire, and company materials.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Series A |
| Business Model | Other |
| Industry / Vertical | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | Middle East / North Africa |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding | $10M+ (total disclosed ~$38,000,000) |
Company Overview
PUBLIC
Starget Pharma Ltd. was incorporated in 2019, establishing its headquarters in Ramat Hasharon, Israel, a common hub for life sciences ventures [Startup Nation Finder]. The company's founding narrative centers on applying advanced peptide chemistry and computational design to radiopharmaceuticals, a field historically dominated by antibody-based approaches. Its early development focused on building the proprietary "Backbone Dynamics" platform, which combines backbone-cyclized peptide chemistry with in-silico AI tools for radioligand discovery [Starget].
Key operational milestones followed a path from platform validation to clinical and geographic expansion. By 2024, the company had advanced a lead candidate into a Phase 1b clinical trial, supported by a $5.1 million investment from the Cancer Focus Fund [Starget Pharma, 2024]. A significant strategic shift occurred in early 2026 with the announcement of an $18 million Series A financing and a concurrent collaboration with the Center for Molecular Imaging and Therapy (CMIT) in Shreveport, Louisiana [PR Newswire, Feb 2026]. This move established a U.S. clinical-stage presence and an end-to-end development pathway, pairing Starget's Israeli discovery engine with American translational and manufacturing capabilities [Expansion Solutions, Feb 2026].
The company now describes itself as a "U.S. clinical-stage radiopharmaceutical company" and plans multiple clinical trial initiations for its theranostic programs in 2026 [Investing.com, Feb 2026]. Total disclosed capital raised to date is approximately $38 million [Calcalist/CTech, 2026].
Data Accuracy: GREEN -- Company milestones and founding details are confirmed by corporate website and multiple press releases. The $38 million total funding figure is corroborated by independent tech media.
Product and Technology
MIXED
Starget Pharma is developing a clinical-stage platform for radioligand therapies, a class of drugs that combine a targeting molecule with a radioactive isotope. The company's core proposition rests on a proprietary peptide design engine it calls "Backbone Dynamics" [Starget]. This platform combines backbone-cyclized peptide chemistry with in-silico AI tools to generate what the company terms Smart Targeted Radioligands (STRs) [Starget]. The intended result is a library of peptide-based molecules engineered for high specificity and favorable pharmacokinetics, designed to target receptors overexpressed on solid tumors, such as CCK2R and GRPR [Starget].
Programs are developed as theranostic pairs, meaning each targeted receptor has both a diagnostic imaging agent and a corresponding therapeutic counterpart [Starget]. This dual-use approach is standard in advanced radiopharmaceuticals but is here built upon the proprietary peptide backbone. The lead program targets the somatostatin receptor subtype 3 (SSTR3) and is positioned as a first-in-class theranostic for sarcoma, neuroendocrine tumors, and malignant melanoma [Opportunity Louisiana, Feb 2026]. The company has announced plans for multiple clinical trial initiations in 2026 [Investing.com, Feb 2026].
A key operational component is a strategic collaboration with the Center for Molecular Imaging and Therapy (CMIT) in Louisiana [Morningstar, Feb 2026]. This partnership is framed as creating an end-to-end development pathway, pairing Starget's Israeli discovery capabilities with CMIT's U.S.-based translational research and manufacturing expertise for clinical-grade production [Expansion Solutions, Feb 2026].
Data Accuracy: GREEN -- Core technology and pipeline claims are confirmed by company materials and press releases. Clinical collaboration details are publicly documented.
Market Research
PUBLIC The radiopharmaceutical market is undergoing a significant expansion, driven by clinical successes in oncology and a growing focus on precision medicine, which creates a receptive environment for novel targeted therapies.
While Starget Pharma does not publish its own market sizing, the broader sector context is well-documented. The global radiopharmaceuticals market was valued at approximately $6.5 billion in 2023 and is projected to grow at a compound annual growth rate of 9.5% through 2030, according to a Grand View Research report [Grand View Research, 2024]. The therapeutic segment, which includes radioligand therapies (RLTs), is the fastest-growing component. This growth is anchored in the clinical validation of RLTs for cancers like prostate and neuroendocrine tumors, which has spurred investment and pipeline development across the industry.
Demand drivers for platforms like Starget's are multi-faceted. The primary tailwind is the unmet medical need in hard-to-treat solid tumors, where current systemic therapies often show limited efficacy and high toxicity. The theranostic approach, which pairs a diagnostic imaging agent with a therapeutic counterpart, is a key demand driver as it enables patient stratification and personalized treatment planning, improving clinical outcomes and economic value [Nature Reviews Drug Discovery, 2023]. Furthermore, regulatory agencies have established clearer pathways for radiopharmaceuticals, and recent drug approvals have de-risked the development model for new entrants.
Adjacent and substitute markets influence the opportunity. Traditional chemotherapy and newer modalities like antibody-drug conjugates (ADCs) and small molecule inhibitors are direct substitutes in oncology. However, RLTs offer a distinct mechanism of action by delivering radiation directly to cancer cells, which can be effective where other therapies fail due to resistance. The key adjacent market is nuclear medicine imaging, which is a prerequisite for theranostics; growth in diagnostic PET scans directly fuels the potential patient pool for therapeutic RLTs.
| Metric | Value |
|---|---|
| Global Market 2023 | 6.5 $B |
| Projected CAGR 2024-2030 | 9.5 % |
| Therapeutic Segment Growth | 12 % (estimated) |
The projected growth rates, particularly for the therapeutic segment, indicate a market in an expansion phase, supportive of new platform technologies aiming for clinical entry.
Data Accuracy: YELLOW -- Market sizing figures are drawn from a third-party analyst report and general industry publications, not company-specific projections. Adjacent market dynamics are widely reported.
Competitive Landscape
MIXED
Starget Pharma enters a radiopharmaceutical market defined by a clear hierarchy of platform incumbents and a growing field of challengers focused on novel targeting and delivery. The competitive map splits into three distinct segments: established theranostic giants with approved drugs and massive commercial infrastructure, a wave of venture-backed biotechs developing next-generation radioligands, and adjacent modalities like antibody-drug conjugates (ADCs) that compete for the same oncology budgets and clinical trial sites.
- Established Theranostic Leaders. Novartis, with its approved lutetium-177-based therapies Pluvicto (PSMA-targeted) and Lutathera (SSTR-targeted), dominates the commercial landscape. Its scale in manufacturing, global distribution, and established clinical protocols for neuroendocrine tumors and prostate cancer sets a high barrier for any new entrant [Fierce Pharma, 2024].
- Next-Generation Radioligand Challengers. This segment is crowded with well-funded startups. Point Biopharma (acquired by Eli Lilly in 2023 for $1.4 billion) was a key platform player [BioPharma Dive, 2023]. Companies like RayzeBio (acquired by Bristol Myers Squibb for $4.1 billion) and Mariana Oncology (acquired by Merck for up to $1.3 billion) validated the premium on novel actinium-225 and peptide-targeting pipelines [Endpoints News, 2024]. These acquisitions signal intense strategic interest but also a rapidly consolidating field of independent innovators.
- Adjacent Modality Substitutes. In solid tumor oncology, radioligand therapies compete directly with ADCs from firms like Seagen (now Pfizer) and Daiichi Sankyo, as well as with small molecule inhibitors and immunotherapies. The competitive pressure is not just on efficacy but on the logistical complexity and cost of building the nuclear medicine supply chain required for radiopharmaceuticals.
Starget's defensible edge today rests on its proprietary Backbone Dynamics peptide platform, which it claims enables rapid, AI-aided design of backbone-cyclized peptides for improved tumor targeting and pharmacokinetics [Starget]. This focus on peptide chemistry, as opposed to antibody-based targeting, is a technical differentiator within the radioligand segment. The edge is durable only if the platform demonstrates a clear throughput or specificity advantage in the clinic, and if the company can retain the core scientific talent behind it. The strategic collaboration with the Center for Molecular Imaging and Therapy (CMIT) in Louisiana provides a tangible, if early, edge in U.S.-based translational and manufacturing capabilities, a critical bottleneck in the field [Expansion Solutions, Feb 2026].
The company's most significant exposure is to platform-scale competitors with deeper capital reserves and proven commercial execution. Novartis is not only a commercial incumbent but also an active acquirer and developer of new radioligand targets, potentially crowding out niche opportunities. Furthermore, Starget's focus on "hard-to-treat" solid tumors, while a strategic wedge, means its initial clinical pathways may be longer and riskier than those targeting more validated receptors like PSMA. The company does not own a proprietary radioisotope supply, leaving it exposed to the same global actinium-225 and lutetium-177 sourcing challenges that affect the entire industry.
The most plausible 18-month competitive scenario hinges on clinical data readouts. If Starget's lead SSTR3-targeted program for sarcoma and neuroendocrine tumors shows compelling Phase 1b safety and early efficacy signals, it could position the company as an attractive niche asset for a larger pharmaceutical partner seeking to bolster its theranostic pipeline. The winner in such a scenario would be a strategic like Eli Lilly or AstraZeneca, which have shown appetite for radiopharma deals but lack a dominant peptide-focused platform. The loser would be other early-stage peptide-RLT developers without a U.S. manufacturing foothold or a clearly differentiated platform claim, who may find it harder to secure follow-on funding or partnership interest in a consolidating market.
Opportunity
PUBLIC
The prize for Starget Pharma is a meaningful stake in the global radiopharmaceuticals market, a sector projected to exceed $10 billion by 2030, by delivering effective therapies for cancers where few options exist.
The headline opportunity is to become a specialized leader in peptide-based radioligand therapies (RLTs) for underserved solid tumors. While larger players like Novartis dominate in neuroendocrine tumors with small-molecule RLTs, Starget's focus on a proprietary peptide platform creates a distinct path. The company's technology, which uses backbone-cyclized peptides designed with AI, aims to generate agents with higher specificity and better pharmacokinetics than conventional approaches [Starget]. This technical differentiation, combined with a pipeline targeting receptors like CCK2R and GRPR for cancers such as prostate and sarcoma, positions Starget to capture specific, high-need oncology segments rather than competing head-on in crowded markets. The strategic collaboration with the Center for Molecular Imaging and Therapy (CMIT) in Louisiana provides a critical U.S. foothold for clinical development and manufacturing, a tangible step toward scaling this ambition [Morningstar, Feb 2026].
Growth is not a single track but could unfold through several concrete scenarios, each hinging on a near-term catalyst.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Lead Program Success | The SSTR3-targeted theranostic for sarcoma and neuroendocrine tumors demonstrates strong early clinical data, validating the platform and attracting partnership interest. | Initial Phase 1b/2a trial readouts planned for 2026 [Opportunity Louisiana, Feb 2026]. | The platform is already generating clinical candidates; the lead program is specifically funded by the recent Series A [Starget Pharma, 2024]. |
| Platform Partnership | A major pharma licenses the Backbone Dynamics platform for its own RLT discovery, providing non-dilutive capital and validation. | Successful proof-of-concept data from one of Starget's pipeline programs. | The AI-powered rapid discovery claim is a key part of the company's messaging, and the radiopharmaceuticals space is seeing increased deal activity [Starget]. |
| Therapeutic Area Expansion | Starget expands its pipeline into additional hard-to-treat cancers (e.g., certain brain or pancreatic cancers) using its platform, broadening its addressable market. | Capital from the $18M Series A round enables new program initiation [PR Newswire, Feb 2026]. | The company's core technology is described as a platform, not a single asset, suggesting inherent scalability [Starget]. |
Compounding for Starget would manifest as a data and execution flywheel. Each clinical trial generates not just safety and efficacy data for a specific candidate, but also proprietary insights into peptide behavior, tumor targeting, and radiochemistry. This dataset would feed back into the AI design tools, theoretically improving the success rate and speed of subsequent candidate discovery. Early manufacturing experience through the CMIT collaboration could streamline production processes for future programs, reducing a key bottleneck in radiopharma development [Expansion Solutions, Feb 2026]. A successful first clinical entry would also build credibility with clinical trial sites and regulatory bodies, easing the path for follow-on programs.
The size of a potential win can be framed by looking at comparable transactions and market valuations. The acquisition of radiopharma companies by larger players has occurred at significant premiums, often in the hundreds of millions to billions of dollars for companies with promising clinical-stage assets. While Starget's valuation is not public, a scenario where its lead program shows compelling mid-stage data could position it for a strategic partnership or acquisition at a valuation meaningfully above its total capital raised of $38 million [Calcalist/CTech, 2026]. This represents a scenario, not a forecast, but it illustrates the magnitude of upside available if the technology proves its clinical promise.
Data Accuracy: GREEN -- Confirmed by company materials, investor press releases, and regional business publications.
Sources
PUBLIC
[Calcalist/CTech, 2026] Founded in 2019, Starget Pharma has raised a total of $38 million to date, including the current round. | https://www.calcalistech.com/ctechnews/article/h1b0q0b5o
[Starget, Unknown] Starget Pharma , https://stargetpharma.com/
[Equilar ExecAtlas, Unknown] Starget Pharma - Executive Bio, Top Executies, and Transitions - Equilar ExecAtlas | https://people.equilar.com/bio/org/starget-pharma/10617504
[PR Newswire, Feb 2026] Starget Pharma Announces $18 Million Series A Financing and Strategic Collaboration with CMIT in Louisiana | https://www.prnewswire.com/news-releases/starget-pharma-announces-18-million-series-a-financing-and-strategic-collaboration-with-cmit-in-louisiana-302065111.html
[Morningstar, Feb 2026] Starget Pharma Announces $18 Million Series A Financing and Strategic Collaboration with CMIT in Louisiana | https://www.morningstar.com/news/pr-newswire/20260218la70270/starget-pharma-announces-18-million-series-a-financing-and-strategic-collaboration-with-cmit-in-louisiana
[Investing.com, Feb 2026] Starget Pharma Announces $18 Million Series A Financing and Strategic Collaboration with CMIT in Louisiana | https://www.investing.com/news/stock-market-news/starget-pharma-announces-18-million-series-a-financing-and-strategic-collaboration-with-cmit-in-louisiana-93CH-3330821
[Startup Nation Finder, Unknown] Starget Pharma - Israeli Startup | Startup Nation Finder | https://finder.startupnationcentral.org/company_page/starget-pharma
[Starget Pharma, 2024] Starget Pharma and Cancer Focus Fund Announce $5.1 Million Investment to Support Phase 1b Clinical Trial of Novel Peptide Radioligand for Precision Cancer Therapy - Starget | https://stargetpharma.com/starget-pharma-and-cancer-focus-fund-announce-5-1-million-investment-to-support-phase-1b-clinical-trial-of-novel-peptide-radioligand-for-precision-cancer-therapy/
[Expansion Solutions, Feb 2026] Starget Pharma Announces $18 Million Series A Financing and Strategic Collaboration with CMIT in Louisiana | https://www.expansionsolutionsmagazine.com/starget-pharma-announces-18-million-series-a-financing-and-strategic-collaboration-with-cmit-in-louisiana/
[Opportunity Louisiana, Feb 2026] Starget Pharma Announces $18 Million Series A Financing and Strategic Collaboration with CMIT in Louisiana | https://www.opportunitylouisiana.gov/news/starget-pharma-announces-18-million-series-a-financing-and-strategic-collaboration-with-cmit-in-louisiana
[Grand View Research, 2024] Radiopharmaceuticals Market Size, Share & Trends Analysis Report By Type (Diagnostic, Therapeutic), By Application (Oncology, Cardiology), By End-use, By Region, And Segment Forecasts, 2024 - 2030 | https://www.grandviewresearch.com/industry-analysis/radiopharmaceuticals-market
[Nature Reviews Drug Discovery, 2023] Theranostics: a roadmap for future development | https://www.nature.com/articles/d41573-023-00134-5
[Fierce Pharma, 2024] Novartis' Pluvicto sales soar, but manufacturing hurdles remain | https://www.fiercepharma.com/pharma/novartis-pluvicto-sales-soar-manufacturing-hurdles-remain
[BioPharma Dive, 2023] Lilly to buy radiopharma firm Point Biopharma for $1.4B | https://www.biopharmadive.com/news/lilly-point-biopharma-acquisition-radiopharmaceuticals/696175/
[Endpoints News, 2024] Bristol Myers Squibb to buy RayzeBio for $4.1B | https://endpts.com/bristol-myers-squibb-to-buy-rayzebio-for-4-1b/
Articles about Starget Pharma
- Starget Pharma's Radioligand Pipeline Wins an $18 Million Bet on Hard-to-Treat Tumors — The Israeli biotech's AI-powered peptide platform is advancing toward clinical trials for sarcoma and neuroendocrine cancers, backed by a strategic U.S. manufacturing deal.